Two rapidly expanding multidistrict litigations, the GLP-1 Receptor Agonists MDL (3094) and the Depo-Provera Brain Tumor MDL (3140), are reshaping pharmaceutical mass-tort practice across the United States.
GLP-1 Drug Litigation: Ozempic, Wegovy, and Mounjaro Under Scrutiny
Filed in early 2025 and now comprising over 1,800 cases, the GLP-1 MDL in the Eastern District of Pennsylvania consolidates claims that popular diabetes and weight-loss drugs cause severe gastrointestinal injury and optic-nerve damage.
Key developments include:
- The court’s August 2025 ruling denying dismissal of 12 claims, allowing failure-to-warn and design-defect counts to move forward.
- Growing evidence from post-marketing studies linking long-term GLP-1 use to gastroparesis and intestinal obstruction.
- Anticipated bellwether selections in mid-2026, expected to test causation theories built on pharmacovigilance and adverse-event data.
These cases mark one of the fastest-forming pharmaceutical MDLs in recent history, propelled by skyrocketing consumer use and off-label prescribing.
Depo-Provera Brain-Tumor Litigation Expands
Parallel proceedings in the Western District of Missouri focus on Depo-Provera (depot medroxyprogesterone acetate), alleging the long-term contraceptive injection causes intracranial meningiomas.
As of November 2025, more than 1,200 cases are pending. Pfizer’s pending federal pre-emption motion could determine the viability of many claims and set new precedent on the boundaries of FDA labeling immunity.
The litigation follows mounting scientific evidence, including studies published in The BMJ (2024) and JAMA Neurology (2025)—that long-term DMPA use increases meningioma risk by more than twofold.
Strategic Insights for Attorneys
- Early Expert Readiness: Courts expect robust causation theories at the first case-management conference under the new Rule 16.1 framework.
- Pre-emption and Labeling Defenses: Defense teams are pressing Mensing and Buckman arguments; plaintiffs counter with failure-to-update and post-marketing-data claims.
- Funding and Collaboration: The cost of early expert development favors consortium models and co-counsel structures similar to those seen in talc and opioid litigation.
Implications for the Bar
These MDLs illustrate the broadening scope of pharmaceutical accountability, from legacy drugs to next-generation biologics. For mass-tort practitioners, they signal a future defined by faster consolidations, science-driven pleadings, and aggressive pre-emption battles.
Join the Legal Effort
Blue Sky Legal continues to track both the GLP-1 and Depo-Provera MDLs, offering litigation analysis and coordination support to firms nationwide.
If your team is pursuing pharmaceutical injury claims or evaluating entry into these MDLs, contact Blue Sky Legal’s Pharmaceutical Litigation Group for strategic intelligence, case-evaluation tools, and partnership opportunities.
Together, we can advance the standards of pharmaceutical accountability and strengthen outcomes for plaintiffs across the nation.
